SYN-Tech Chem & Pharm Co Ltd (TWO:1777) — Market Cap & Net Worth
Market Cap & Net Worth: SYN-Tech Chem & Pharm Co Ltd (1777)
SYN-Tech Chem & Pharm Co Ltd (TWO:1777) has a market capitalization of $99.61 Million (NT$3.16 Billion) as of May 4, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #19197 globally and #1082 in its home market, demonstrating a -0.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SYN-Tech Chem & Pharm Co Ltd's stock price NT$70.90 by its total outstanding shares 44592000 (44.59 Million). Analyse how efficiently does SYN-Tech Chem & Pharm Co Ltd generate cash to see how efficiently the company converts income to cash.
SYN-Tech Chem & Pharm Co Ltd Market Cap History: 2015 to 2026
SYN-Tech Chem & Pharm Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $83.98 Million to $99.61 Million (3.18% CAGR).
SYN-Tech Chem & Pharm Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SYN-Tech Chem & Pharm Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.08x
SYN-Tech Chem & Pharm Co Ltd's market cap is 0.08 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.40x
SYN-Tech Chem & Pharm Co Ltd's market cap is 0.40 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $97.44 Million | $766.79 Million | $158.47 Million | 0.13x | 0.61x |
| 2017 | $75.30 Million | $694.99 Million | $59.78 Million | 0.11x | 1.26x |
| 2018 | $83.79 Million | $784.83 Million | $153.99 Million | 0.11x | 0.54x |
| 2019 | $92.54 Million | $946.41 Million | $159.47 Million | 0.10x | 0.58x |
| 2020 | $89.81 Million | $983.79 Million | $186.74 Million | 0.09x | 0.48x |
| 2021 | $83.14 Million | $893.23 Million | $177.16 Million | 0.09x | 0.47x |
| 2022 | $110.41 Million | $986.30 Million | $295.29 Million | 0.11x | 0.37x |
| 2023 | $115.67 Million | $1.11 Billion | $251.01 Million | 0.10x | 0.46x |
| 2024 | $132.34 Million | $1.26 Billion | $393.28 Million | 0.11x | 0.34x |
| 2025 | $103.68 Million | $1.30 Billion | $261.61 Million | 0.08x | 0.40x |
Competitor Companies of 1777 by Market Capitalization
Companies near SYN-Tech Chem & Pharm Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to SYN-Tech Chem & Pharm Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
SYN-Tech Chem & Pharm Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, SYN-Tech Chem & Pharm Co Ltd's market cap moved from $83.98 Million to $ 99.61 Million, with a yearly change of 3.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$99.61 Million | -3.93% |
| 2025 | NT$103.68 Million | -21.66% |
| 2024 | NT$132.34 Million | +14.41% |
| 2023 | NT$115.67 Million | +4.76% |
| 2022 | NT$110.41 Million | +32.80% |
| 2021 | NT$83.14 Million | -7.43% |
| 2020 | NT$89.81 Million | -2.95% |
| 2019 | NT$92.54 Million | +10.44% |
| 2018 | NT$83.79 Million | +11.28% |
| 2017 | NT$75.30 Million | -22.73% |
| 2016 | NT$97.44 Million | +16.04% |
| 2015 | NT$83.98 Million | -- |
End of Day Market Cap According to Different Sources
On May 4th, 2026 the market cap of SYN-Tech Chem & Pharm Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $99.61 Million USD |
| MoneyControl | $99.61 Million USD |
| MarketWatch | $99.61 Million USD |
| marketcap.company | $99.61 Million USD |
| Reuters | $99.61 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SYN-Tech Chem & Pharm Co Ltd
SYN-TECH Chem. & Pharm. Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) in Taiwan, Asia, Europe, the Americas, and internationally. The company offers test drugs and surfactants, as well as various Chinese, Western, and animal medicines. It also provides products in various categories, such as anticoagulant, attention deficit hyperactivity disorder, skeletal muscle relax… Read more